Tirzepatide Peptide for Sale

Compare tirzepatide research peptide prices by vial size and cost per mg. Review available COAs, discount codes and stock, then visit your chosen vendor.

Compare tirzepatide research vials by price, cost per mg, available COAs and stock. Choose a vial size, review the options, and visit your preferred vendor.

How much does Tirzepatide cost per month?

An illustrative Tirzepatide cost model works out to about $14.42 per month: EZ Peptides's listed 600 mg purchase quantity at $799.20 with code wpa10, divided into 2.5 mg amounts once weekly. This quantity provides 240.0 nominal portions — about 240.0 weeks at the selected cadence, before preparation losses or stability limits — for roughly $3.33 per week or $14.42 per 4.33-week month. Vial count and milligrams per vial must be checked separately. This is illustrative arithmetic combining independently selected lifetime modal inputs, not a verified most-common joint protocol. The amount distribution includes 19,970 calculator runs; overall cadence comes from 2,216 separate lifetime frequency responses across amounts. Calculator inputs are not confirmed administration or recommendations.

Use the live cost-per-month card to change nominal purchase quantity, amount, cadence and vendor strategy. Recorded purity can be compared separately; it is not independent verification or a quality guarantee. Confirm package composition and checkout price with the vendor.

About Tirzepatide

FDA-approvedAlso known as: Mounjaro · Zepbound · LY3298176

Tirzepatide is the dual GIP/GLP-1 receptor agonist behind Mounjaro and Zepbound, and the research peptide most often sourced for weight-management and metabolic studies. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]

What to check before you buy Tirzepatide:

  • A third-party COA showing ≥99% purity by HPLC plus mass-spec confirmation of the 39-amino-acid sequence — not just an in-house "lab tested" badge.
  • A COA dated within the last 6–12 months that matches the exact vial size and batch you are buying.
  • Accurate vial fill: a 10mg label should assay close to 10mg. Under-filled or mislabeled vials are a common quality failure, and they throw off every reconstitution calculation.

The SURPASS program established A1C reductions of roughly 2.0–2.4% in type 2 diabetes at 5–15mg weekly,[2] and SURMOUNT-1 (Jastreboff et al., NEJM 2022) reported mean weight reduction of ~20.9% at 72 weeks on the 15mg arm.[3] Active trials extend tirzepatide into heart failure with preserved ejection fraction (SUMMIT), obstructive sleep apnea (SURMOUNT-OSA), and metabolic dysfunction-associated steatohepatitis (SYNERGY-NASH).

Regulatory: FDA-approved as Mounjaro (T2D, 2022) and Zepbound (obesity, 2023). Research-grade tirzepatide for in vitro / non-clinical use only.

Read the full mechanism & research breakdown

Tirzepatide: Mechanisms, Half-Life & Research Data

A skimmable deep dive into how Tirzepatide works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.

How it works

Tirzepatide is a 39-amino-acid synthetic peptide that binds two different gut-hormone receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor.[4] The GLP-1 arm slows gastric emptying, amplifies glucose-dependent insulin release, suppresses glucagon, and acts on hypothalamic appetite centers — the same machinery as semaglutide. The GIP arm adds a second incretin signal that appears to amplify weight loss and may improve how the body handles fat storage; one leading hypothesis is that GIP also reduces the nausea load of pure GLP-1 agonism by modulating brainstem signalling.[5] A C-20 fatty-diacid sidechain binds albumin, extending the half-life to roughly 5 days and supporting once-weekly subcutaneous dosing.

Active research areas

  • Type 2 diabetes (SURPASS)
    The SURPASS program of Phase 3 trials established A1C reductions of roughly 2.0–2.4% at 5–15mg weekly across monotherapy, add-on, and head-to-head comparisons; SURPASS-2 showed tirzepatide outperforming semaglutide 1mg on both A1C and weight at 40 weeks.[2]
  • Obesity (SURMOUNT-1 and SURMOUNT-2)
    SURMOUNT-1 reported mean weight reduction of approximately 20.9% at 72 weeks on the 15mg arm in adults with obesity but without diabetes,[3] and SURMOUNT-2 showed roughly 15.7% mean weight reduction at 72 weeks in adults with T2D and obesity — historically a population that loses less weight on incretin therapy.[6]
  • Heart failure with preserved ejection fraction (SUMMIT)
    SUMMIT reported that tirzepatide reduced the composite of cardiovascular death or worsening heart failure events and improved KCCQ quality-of-life scores in adults with obesity-related HFpEF — the first incretin therapy with a positive HFpEF outcomes readout.[7]
  • Obstructive sleep apnea (SURMOUNT-OSA)
    SURMOUNT-OSA reported that tirzepatide reduced the apnea–hypopnea index by roughly 50–60% at 52 weeks in adults with moderate-to-severe OSA and obesity, with the benefit tracking weight loss; the FDA expanded the Zepbound label to include moderate-to-severe OSA in adults with obesity on the strength of this trial.[8]
  • Metabolic dysfunction-associated steatohepatitis (SYNERGY-NASH)
    SYNERGY-NASH reported that 44–62% of participants on the 5–15mg arms achieved MASH resolution without worsening fibrosis at 52 weeks, versus 10% on placebo, with a dose-dependent fibrosis-improvement signal that did not reach the pre-specified statistical threshold.[9]
  • Cardiovascular outcomes (SURPASS-CVOT)
    SURPASS-CVOT is a long-running active-controlled outcomes trial comparing tirzepatide against dulaglutide for major adverse cardiovascular events in adults with T2D and established cardiovascular disease, with a primary readout expected in 2026.[10]
  • Alzheimer's disease (early-stage trials)
    A registered Phase 2 investigator-initiated trial is testing tirzepatide in adults with mild cognitive impairment and early Alzheimer's disease, building on the broader GLP-1 class signal in dementia research; this is early-stage work, not yet a confirmatory program.[12]
Open questions & leading hypotheses (3)
  • Hypothesis: The GIP arm is what makes tirzepatide produce larger weight loss than pure GLP-1 agonists, not just stronger GLP-1 signalling.
    Evidence: SURPASS-2 reported that tirzepatide 15mg outperformed semaglutide 1mg on weight loss in T2D,[2] and pre-clinical work indicates that adding GIP-receptor activation amplifies the weight-loss effect of GLP-1 agonism and may reduce nausea.[4][5] Counter-evidence: the dose of semaglutide used in SURPASS-2 (1mg) is the T2D dose, not the higher 2.4mg obesity dose, so the head-to-head comparison does not isolate the GIP contribution cleanly; whether GIP-receptor agonism, antagonism, or biased agonism is what matters is still actively debated.
  • Hypothesis: Tirzepatide causes meaningful lean-mass loss alongside its fat-mass loss, comparable to other rapid weight-loss interventions.
    Evidence: An exploratory body-composition substudy of SURMOUNT-1 reported that roughly 25% of total weight lost was lean tissue, which is broadly in line with what is seen in dietary weight-loss studies of similar magnitude.[11] Counter-evidence: lean mass is not the same thing as functional muscle, and the long-term implications of this lean-mass loss in older adults — who are also the population most likely to be prescribed tirzepatide for HFpEF or OSA — have not yet been characterised in controlled trials.
  • Hypothesis: The cardiovascular, hepatic, and OSA benefits of tirzepatide are driven primarily by weight loss rather than by direct receptor effects on those tissues.
    Evidence: Across SUMMIT, SURMOUNT-OSA, and SYNERGY-NASH, the magnitude of clinical benefit tracks the magnitude of weight loss closely.[7][8][9] Counter-evidence: GLP-1 receptors are expressed in the heart, kidney, and central nervous system, and weight-loss-independent effects (anti-inflammatory, natriuretic, direct cardiac) have been demonstrated for the class; the question of how much of tirzepatide's organ-level benefit is "just" weight loss vs. direct receptor signalling will only be resolved by trials that match for weight loss across arms.
What community users report

Anecdotal — not controlled-trial evidence

Across r/tirzepatidecompound and r/Mounjaro, users running both prescription and research-grade protocols most often report rapid appetite suppression beginning within the first one to two weeks, weekly weight loss of roughly 1–2lb on titration doses, and a side-effect profile dominated by nausea, constipation, and sulphur burps that frequently forces slower titration than the SURPASS or SURMOUNT trial protocols use.[13][14] Many threads describe a "food noise" reduction — a quieting of intrusive thoughts about food — that users find as valuable as the weight loss itself, and a smaller cohort reports rebound hunger and weight regain after discontinuation that aligns with the published STEP-1 extension data from the semaglutide class. **These reports are anecdotal and have not been validated in controlled trials.** They are useful for understanding what people who have already chosen to use tirzepatide are experiencing, but they do not establish that any specific titration schedule, off-label use, or research-grade protocol is safe or effective.

Sources & references (14)

Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.

  1. [1]FDA approval letter, Mounjaro (tirzepatide), May 2022 link
  2. [2]Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2). NEJM 2021;385:503–515. · PMID: 34170647 link
  3. [3]Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205–216. · PMID: 35658024 link
  4. [4]Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor co-agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab 2018;18:3–14. · PMID: 30473097 link
  5. [5]Samms RJ et al. How may GIP enhance the tolerability of GLP-1 receptor agonists? Trends Endocrinol Metab 2020;31:410–421. · PMID: 32396843 link
  6. [6]Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402:613–626. · PMID: 37385275 link
  7. [7]Packer M et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). NEJM 2025;392:427–437. · PMID: 39555826 link
  8. [8]Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). NEJM 2024;391:1193–1205. · PMID: 38912654 link
  9. [9]Loomba R et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH). NEJM 2024;391:299–310. · PMID: 38856224 link
  10. [10]ClinicalTrials.gov: SURPASS-CVOT (NCT04255433) — Cardiovascular and renal outcomes with tirzepatide versus dulaglutide in T2D. link
  11. [11]Look M et al. Body composition changes during tirzepatide treatment: an exploratory analysis of the SURMOUNT-1 trial. Diabetes Obes Metab 2024;26:4368–4377. · PMID: 39021048 link
  12. [12]ClinicalTrials.gov: Tirzepatide for the Treatment of Alzheimer's Disease (NCT05930990) — investigator-initiated Phase 2 study of tirzepatide in mild cognitive impairment and early Alzheimer's disease. link
  13. [13]Community report — r/tirzepatidecompound weekly experience threads (subreddit), accessed May 2026. link
  14. [14]Community report — r/Mounjaro dose titration and side-effect discussions (subreddit), accessed May 2026. link

What Tirzepatide Costs Right Now

WPA currently tracks Tirzepatide from 12 distinct vendors across 58 separate Tirzepatide listings. In-stock Tirzepatide vials run from $26.10 to $799.20 — a 30.6x spread for the same compound. Ameano Peptides holds the lowest sticker price at $26.10. Normalized to milligrams, Tirzepatide costs $1.33/mg to $12.11/mg on this page. The best per-milligram value is the listed 600 mg purchase quantity from EZ Peptides.

Tirzepatide is stocked in 14 sizes: 10 mg listed quantity; vial count not recorded; 100 mg listed quantity; vial count not recorded; 120 mg listed quantity; vial count not recorded; 150 mg listed quantity; vial count not recorded; 15 mg listed quantity; vial count not recorded; 200 mg listed quantity; vial count not recorded; 20 mg listed quantity; vial count not recorded; 300 mg listed quantity; vial count not recorded; 30 mg listed quantity; vial count not recorded; 40 mg listed quantity; vial count not recorded; 50 mg listed quantity; vial count not recorded; 600 mg listed quantity; vial count not recorded; 60 mg listed quantity; vial count not recorded; 75 mg listed quantity; vial count not recorded. 57 of the 58 tracked listings are in stock right now. Because vials of different strengths rarely scale linearly in price, the per-milligram column is the only fair way to rank them.

Ranked by true cost per milligram, the Tirzepatide listings WPA tracks are: EZ Peptides — 600mg at $799.20 ($1.33/mg), COA purity 99.93%; Ameano Peptides — 60mg at $81.90 ($1.36/mg), COA purity 99.94%; Southern Aminos — 60mg at $84.15 ($1.40/mg), COA purity 99.86%; Southern Aminos — 40mg at $67.15 ($1.68/mg), COA purity 99.83%; Ameano Peptides — 30mg at $52.20 ($1.74/mg), COA purity 99.94%.

Tirzepatide COA Coverage Across Tracked Vendors

47 of the 58 tracked Tirzepatide listings (81%) are marked as having COA availability in WPA's listing data; this marker is not independent verification. A purity value is recorded for 47 listings; purity alone does not establish identity or independent testing. The recorded purity values range from 99.00% to 99.94%. 40 listings record more Tirzepatide in the vial than the label claims; check the vendor's report and batch before drawing conclusions. The latest COA date recorded in WPA's listing data is 11/26.

To assess a COA, inspect the actual report for the independent lab, test date, and a batch and vial size matching the Tirzepatide offer. WPA's listing fields do not establish that a report was independently verified.

Tirzepatide Calculator Input Observations

In lifetime Tirzepatide calculator inputs, 2.5mg is the most frequent entered amount (4,109 of 19,970 runs). Separately, Weekly (1x/wk) is the most frequent overall cadence (1,927 of 2,214 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 2.5mg, Weekly (1x/wk) is most frequent (521 of 589 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. As nominal quantity arithmetic only, 600 mg of listed product divided by 2.5 mg gives roughly 240 portions before preparation losses. This does not establish vial count, stability after preparation, or cycle length.

Tirzepatide Discount Codes

58 of the 58 tracked Tirzepatide listings carry a WPA researcher discount code. The largest live discount is 50% off. Every price and per-milligram figure on this page is the post-discount number, so you are never comparing a discounted listing against an undiscounted one. Codes change and some exclude sale items or carry order minimums.

About Tirzepatide

Tirzepatide is the dual GIP/GLP-1 receptor agonist behind Mounjaro and Zepbound, and the research peptide most often sourced for weight-management and metabolic studies. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.

Tirzepatide is tracked under the Weight Loss category on WPA. Its reported half-life is ~5 days. Calculator inputs do not establish why a cadence was selected or validate a protocol. FDA-approved as Mounjaro (T2D, 2022) and Zepbound (obesity, 2023).

How to Read the Tirzepatide Comparison

  • Price per milligram — Every Tirzepatide listing is normalized to $1.33/mg-style unit pricing, so a small cheap vial cannot hide a worse real cost than a larger one.
  • COA metadata and purity — 47 Tirzepatide listings are marked for COA availability, and 47 have a recorded purity value. These fields do not independently verify a report.
  • Vials sizes — The Tirzepatide comparison includes 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg, 75mg, 100mg, 120mg, 150mg, 200mg, 300mg, and 600mg listed purchase quantities. Check package composition separately.
  • Stock status — Live in-stock state for each Tirzepatide listing, refreshed on a recurring basis.

Frequently Asked Questions: Tirzepatide

Is it legal and safe to buy Tirzepatide for research?

In the US, Tirzepatide is sold strictly as a research chemical — legal to buy for laboratory research but not approved for human use. It is the same molecule as the approved GLP-1/GIP drug, but research-grade vials are not FDA-approved and are sold for laboratory use only. The real variable isn't legality, it's quality: unverified suppliers can ship underdosed, impure, or mislabeled material. WPA records COA-related listing fields where supplied, but does not independently verify every report. Inspect the actual batch report and its laboratory, identity testing, and date before drawing conclusions. Right now that screen covers 58 Tirzepatide listings from 12 vendors, 57 of them in stock.

How do I verify a Tirzepatide COA so I'm not getting an underdosed vial?

A Certificate of Analysis (COA) may report tests for a specific Tirzepatide batch. Check that the report identifies the compound (actually tirzepatide, not semaglutide or an underdosed blend), names the laboratory, describes the test method and result, and matches the offered batch and date. A recorded purity value or COA-availability flag in WPA's listing data is not independent verification. Open the vendor listing and inspect the actual report before drawing conclusions. For Tirzepatide specifically, 47 of 58 tracked listings (81%) are marked as having COA availability in WPA's listing data; that marker is not independent verification. A purity value is separately recorded for 47 listings; purity alone does not establish identity or independent testing. The latest COA date recorded in the listing data is 11/26.

Which Tirzepatide vendor should I pick?

There's no single "best" Tirzepatide vendor — it depends on what you weigh most. WPA ranks tracked listings using recorded purity and date fields where available, visitor click activity, price, stock status, and discount data; this ranking is not independent verification of a report. Tirzepatide is one of the most-bought compounds on the site, so lifetime click data is especially meaningful here — but always cross-check the COA date, since high-volume sellers rotate batches often. 12 vendors currently carry Tirzepatide, and EZ Peptides holds the best true value at $1.33/mg on the 600 mg listed purchase quantity. Review the actual report and confirm its batch details before making a decision.

How much does Tirzepatide cost — and how do I know I'm not overpaying?

Judge Tirzepatide by true price per milligram, not the sticker price on one vial — a cheap small vial often costs more per mg than a larger one. It ships in everything from 10 mg up to 60 mg vials, and the big multi-dose vials dramatically lower $/mg over a full titration cycle. Tracked Tirzepatide listings currently run $1.33/mg to $12.11/mg across 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg, 75mg, 100mg, 120mg, 150mg, 200mg, 300mg, 600mg listed purchase quantities (not necessarily single vials). WPA normalizes tracked listings to $/mg, and the live cost-per-month card estimates your spend at the most common dose. The one catch: the lowest $/mg sometimes means buying a bigger vial than your cycle needs.

How much Tirzepatide do I need for one full cycle?

In lifetime Tirzepatide calculator inputs, 2.5mg is the most frequent entered amount (4,109 of 19,970 runs). Separately, Weekly (1x/wk) is the most frequent overall cadence (1,927 of 2,214 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 2.5mg, Weekly (1x/wk) is most frequent (521 of 589 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. Dividing the listed 600 mg purchase quantity by 2.5 mg gives roughly 240 nominal portions before preparation losses; vial count and stability after preparation are separate questions. A cycle requires an independently chosen amount, cadence and time horizon; calculator observations do not supply those decisions. Compare nominal package quantities and model your own selections in the cost card.

Are discount codes available for Tirzepatide?

Participating Tirzepatide vendors may offer WPA researcher discount codes. Codes can change, exclude sale items or carry order minimums. 58 of the 58 tracked Tirzepatide listings carry a code right now, the largest worth 50% off. Each listing shows the recorded code and discounted price where available; confirm the actual package and checkout terms with the vendor.

Lowest priced tirzepatide peptide for sale?

To surface the lowest priced tirzepatide for sale, WPA continuously compares 14 USA suppliers and 956 "for research" products, ranking every verified tirzepatide listing by true cost so the cheapest vials rise to the top. The lowest priced single tirzepatide vial currently starts at $26.10. We currently track 59 tirzepatide products in our system. Pricing is generally refreshed weekly as vendors update stock, prices, and discount codes.